Scipio news

25
February
2020

Scipio bioscience announces its Series A fund raising

A total of €6.0m has been obtained from an international syndicate led by M Ventures (Amsterdam, The Netherlands), the corporate venture capital arm of Merck. The initial shareholders Seventure Partners’ Quadrivum I (Paris, France) and High-Tech Gründerfonds (Bonn, Germany) participated in the capital increase, alongside additional investors Financière Arbevel (Paris, France) and Investiere Venture Capital (Zürich, Switzerland). Read the full press release here.